Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial.
Behnood BikdeliAzita H TalasazFarid RashidiHooman BakhshandehFarnaz RafieeParisa RezaeifarElahe BaghizadehSamira MatinSepehr JamalkhaniOuria TahamtanBabak Sharif-KashaniMohammad Taghi BeigmohammadiMohsen FarrokhpourSeyed Hashem SezavarPooya PayandemehrAli DabbaghKeivan Gohari MoghadamHossein KhaliliMahdi YadollahzadehTaghi RiahiAtefeh AbediniSomayeh LookzadehHamid RahmaniElnaz ZoghiKeyhan MohammadiPardis SadeghipourHoma AbriSanaz TabriziSeyed Masoud MousavianShaghayegh ShahmirzaeiAhmad AminBahram MohebbiSeyed Ehsan ParhizgarRasoul AliannejadVahid EslamiAlireza KashefizadehPaul P DobeshHessam KakavandSeyed Hossein HosseiniShadi ShafaghiSamrand Fattah GhaziAtabak NajafiDavid JimenezAakriti GuptaMahesh V MadhavanSanjum S SethiSahil A ParikhManuel MonrealNaser HadavandAlireza HajighasemiMajid MalekiSaeed SadeghianGregory PiazzaAjay J KirtaneBenjamin W Van TassellGregg W StoneGregory Yoke Hong LipHarlan M KrumholzSamuel Z GoldhaberParham SadeghipourPublished in: Thrombosis and haemostasis (2021)
Intermediate-dose compared with standard-dose prophylactic anticoagulation did not reduce a composite of death, treatment with ECMO, or venous or arterial thrombosis at 90-day follow-up.